Literature DB >> 10592270

Human immunodeficiency virus reverse transcriptase and protease sequence database.

R W Shafer1, D R Jung, B J Betts, Y Xi, M J Gonzales.   

Abstract

The HIV RT and Protease Sequence Database is an online relational database that catalogs evolutionary and drug-related human immunodeficiency virus (HIV) reverse transcriptase (RT) and protease sequence variation (http://hivdb.stanford.edu). The database contains a compilation of nearly all published HIV RT and protease sequences including International Collaboration database submissions (e.g., GenBank) and sequences published in journal articles. Sequences are linked to data about the source of the sequence sample and the antiretroviral drug treatment history of the individual from whom the isolate was obtained. The database is curated and sequences are annotated with data from >230 literature references. Users can retrieve additional data and view alignments of sequence sets meeting specific criteria (e.g., treatment history, subtype, presence of a particular mutation). A gene-specific sequence analysis program, new user-defined queries and nearly 2000 additional sequences were added in 1999.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10592270      PMCID: PMC102477          DOI: 10.1093/nar/28.1.346

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  7 in total

Review 1.  Structural mechanisms of HIV drug resistance.

Authors:  J W Erickson; S K Burt
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

2.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

3.  Maintaining the integrity of human immunodeficiency virus sequence databases.

Authors:  G H Learn; B T Korber; B Foley; B H Hahn; S M Wolinsky; J I Mullins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 4.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Authors:  M S Hirsch; B Conway; R T D'Aquila; V A Johnson; F Brun-Vézinet; B Clotet; L M Demeter; S M Hammer; D M Jacobsen; D R Kuritzkes; C Loveday; J W Mellors; S Vella; D D Richman
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

5.  The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention.

Authors:  D J Hu; T J Dondero; M A Rayfield; J R George; G Schochetman; H W Jaffe; C C Luo; M L Kalish; B G Weniger; C P Pau; C A Schable; J W Curran
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

6.  Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients.

Authors:  R W Shafer; M A Winters; S Palmer; T C Merigan
Journal:  Ann Intern Med       Date:  1998-06-01       Impact factor: 25.391

Review 7.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Authors:  C Tantillo; J Ding; A Jacobo-Molina; R G Nanni; P L Boyer; S H Hughes; R Pauwels; K Andries; P A Janssen; E Arnold
Journal:  J Mol Biol       Date:  1994-10-28       Impact factor: 5.469

  7 in total
  19 in total

1.  A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex.

Authors:  Etsuko Katoh; John M Louis; Toshimasa Yamazaki; Angela M Gronenborn; Dennis A Torchia; Rieko Ishima
Journal:  Protein Sci       Date:  2003-07       Impact factor: 6.725

2.  Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.

Authors:  Joke Snoeck; Rami Kantor; Robert W Shafer; Kristel Van Laethem; Koen Deforche; Ana Patricia Carvalho; Brian Wynhoven; Marcelo A Soares; Patricia Cane; John Clarke; Candice Pillay; Sunee Sirivichayakul; Koya Ariyoshi; Africa Holguin; Hagit Rudich; Rosangela Rodrigues; Maria Belen Bouzas; Françoise Brun-Vézinet; Caroline Reid; Pedro Cahn; Luis Fernando Brigido; Zehava Grossman; Vincent Soriano; Wataru Sugiura; Praphan Phanuphak; Lynn Morris; Jonathan Weber; Deenan Pillay; Amilcar Tanuri; Richard P Harrigan; Ricardo Camacho; Jonathan M Schapiro; David Katzenstein; Anne-Mieke Vandamme
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems.

Authors:  Mala L Radhakrishnan; Bruce Tidor
Journal:  J Chem Inf Model       Date:  2008-05-27       Impact factor: 4.956

4.  Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase.

Authors:  Allison K Delong; Mingham Wu; Diane Bennett; Neil Parkin; Zhijin Wu; Joseph W Hogan; Rami Kantor
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-26       Impact factor: 2.205

Review 5.  Molecular methods and platforms for infectious diseases testing a review of FDA-approved and cleared assays.

Authors:  Rajyasree Emmadi; Jerry B Boonyaratanakornkit; Rangaraj Selvarangan; Venkatakrishna Shyamala; Barbara L Zimmer; Laurina Williams; Bonita Bryant; Ted Schutzbank; Michele M Schoonmaker; Jean A Amos Wilson; Leslie Hall; Preeti Pancholi; Kathryn Bernard
Journal:  J Mol Diagn       Date:  2011-08-25       Impact factor: 5.568

6.  Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.

Authors:  Ingrid A Beck; Madhumita Mahalanabis; Gregory Pepper; Amy Wright; Shannon Hamilton; Erika Langston; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.

Authors:  Ying-Chuan Lin; Zachary Beck; Garrett M Morris; Arthur J Olson; John H Elder
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors:  Terri Watkins; Wolfgang Resch; David Irlbeck; Ronald Swanstrom
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.

Authors:  Bradley C Logsdon; John F Vickrey; Philip Martin; Gheorghe Proteasa; Jay I Koepke; Stanley R Terlecky; Zdzislaw Wawrzak; Mark A Winters; Thomas C Merigan; Ladislau C Kovari
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.